Off-Label Promotion Remains Vulnerable To Prosecution, DoJ Says
Executive Summary
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation
You may also be interested in...
Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
Industry-Sponsored CME Still On FDA Radar, McNeil Exec Says
Industry-sponsored continuing medical education remains on the radar at FDA, McNeil Consumer & Specialty Pharmaceuticals VP-Medical Regulatory Affairs Minnie Baylor-Henry said